These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 8269583)

  • 1. Effects of the methoxymorpholino derivative of doxorubicin and its bioactivated form versus doxorubicin on human leukemia and lymphoma cell lines and normal bone marrow.
    Kühl JS; Durán GE; Chao NJ; Sikic BI
    Cancer Chemother Pharmacol; 1993; 33(1):10-6. PubMed ID: 8269583
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hematotoxicity on human bone marrow- and umbilical cord blood-derived progenitor cells and in vitro therapeutic index of methoxymorpholinyldoxorubicin and its metabolites.
    Ghielmini M; Colli E; Bosshard G; Pennella G; Geroni C; Torri V; D'Incalci M; Cavalli F; Sessa C
    Cancer Chemother Pharmacol; 1998; 42(3):235-40. PubMed ID: 9685059
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Doxorubicin and the alkylating anthracycline 3'-deamino-3'-(3-cyano-4-morpholinyl) doxorubicin: comparative in vitro potency against leukemia and bone marrow cells.
    Beckman RA; McFall PJ; Sikic BI; Smith SD
    J Natl Cancer Inst; 1988 May; 80(5):361-5. PubMed ID: 3357201
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo antitumor activity and host toxicity of methoxymorpholinyl doxorubicin: role of cytochrome P450 3A.
    Quintieri L; Rosato A; Napoli E; Sola F; Geroni C; Floreani M; Zanovello P
    Cancer Res; 2000 Jun; 60(12):3232-8. PubMed ID: 10866316
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolic conversion of methoxymorpholinyl doxorubicin: from a DNA strand breaker to a DNA cross-linker.
    Lau DH; Duran GE; Lewis AD; Sikic BI
    Br J Cancer; 1994 Jul; 70(1):79-84. PubMed ID: 8018545
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antitumor activity of methoxymorpholinyl doxorubicin: potentiation by cytochrome P450 3A metabolism.
    Lu H; Waxman DJ
    Mol Pharmacol; 2005 Jan; 67(1):212-9. PubMed ID: 15465924
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Formation and antitumor activity of PNU-159682, a major metabolite of nemorubicin in human liver microsomes.
    Quintieri L; Geroni C; Fantin M; Battaglia R; Rosato A; Speed W; Zanovello P; Floreani M
    Clin Cancer Res; 2005 Feb; 11(4):1608-17. PubMed ID: 15746066
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure-dependent antitumor activities of novel anthracyclines YM1, YM3, YM4 and YM6: drug transport properties and effects on biomacromolecule synthesis in drug sensitive and resistant leukemia cells.
    Jiang XR; Macey MG; Kelsey SM; Collins PW; Gutteridge CN; Miki T; Adachi K; Yamabe S; Newland AC
    J Chemother; 1993 Oct; 5(5):334-43. PubMed ID: 7508975
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolism of methoxymorpholino-doxorubicin in rat, dog and monkey liver microsomes: comparison with human microsomes.
    Beulz-Riche D; Robert J; Menard C; Ratanasavanh D
    Fundam Clin Pharmacol; 2001 Dec; 15(6):373-8. PubMed ID: 11860524
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transferrin as a drug carrier: Cytotoxicity, cellular uptake and transport kinetics of doxorubicin transferrin conjugate in the human leukemia cells.
    Szwed M; Matusiak A; Laroche-Clary A; Robert J; Marszalek I; Jozwiak Z
    Toxicol In Vitro; 2014 Mar; 28(2):187-97. PubMed ID: 24055890
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of methoxymorpholino anthracycline and cyanomorpholino anthracycline in a sensitive small-cell lung-cancer cell line and its multidrug-resistant but P-glycoprotein-negative and cisplatin-resistant counterparts.
    van der Graaf WT; Mulder NH; Meijer C; de Vries EG
    Cancer Chemother Pharmacol; 1995; 35(4):345-8. PubMed ID: 7828280
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential single- versus double-strand DNA breakage produced by doxorubicin and its morpholinyl analogues.
    Duran GE; Lau DH; Lewis AD; Kühl JS; Bämmler TK; Sikic BI
    Cancer Chemother Pharmacol; 1996; 38(3):210-6. PubMed ID: 8646794
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cellular and karyotypic characterization of two doxorubicin resistant cell lines isolated from the same parental human leukemia cell line.
    Zalcberg JR; Hu XF; Wall DM; Mirski S; Cole S; Nadalin G; De Luise M; Parkin JD; Vrazas V; Campbell L
    Int J Cancer; 1994 May; 57(4):522-8. PubMed ID: 7514153
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Species-differences in disposition and reductive metabolism of methoxymorpholinodoxorubicin (PNU 152243), a new potential anticancer agent.
    Breda M; Benedetti MS; Battaglia R; Castelli MG; Poggesi I; Spinelli R; Hackett AM; Dostert P
    Pharmacol Res; 2000 Feb; 41(2):239-48. PubMed ID: 10623492
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Delivery of methoxymorpholinyl doxorubicin by interleukin 2-activated NK cells: effect in mice bearing hepatic metastases.
    Quintieri L; Rosato A; Amboldi N; Vizler C; Ballinari D; Zanovello P; Collavo D
    Br J Cancer; 1999 Mar; 79(7-8):1067-73. PubMed ID: 10098738
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro hepatic conversion of the anticancer agent nemorubicin to its active metabolite PNU-159682 in mice, rats and dogs: a comparison with human liver microsomes.
    Quintieri L; Fantin M; Palatini P; De Martin S; Rosato A; Caruso M; Geroni C; Floreani M
    Biochem Pharmacol; 2008 Sep; 76(6):784-95. PubMed ID: 18671948
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of doxorubicin in combination with mafosfamide for in vitro elimination of myeloid and lymphoid tumor cells from human bone marrow.
    Domenech J; Georget MT; Gihana E; Colombat P; Brémond JL; Chassaigne M; Lamagnère JP; Binet C
    Bone Marrow Transplant; 1992 Feb; 9(2):101-6. PubMed ID: 1571708
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modulation of etoposide (VP-16) cytotoxicity by verapamil or cyclosporine in multidrug-resistant human leukemic cell lines and normal bone marrow.
    Chao NJ; Aihara M; Blume KG; Sikic BI
    Exp Hematol; 1990 Dec; 18(11):1193-8. PubMed ID: 2226679
    [TBL] [Abstract][Full Text] [Related]  

  • 19. N-benzyladriamycin-14-valerate versus progressively doxorubicin-resistant murine tumours: cellular pharmacology and characterisation of cross-resistance in vitro and in vivo.
    Ganapathi R; Grabowski D; Sweatman TW; Seshadri R; Israel M
    Br J Cancer; 1989 Dec; 60(6):819-26. PubMed ID: 2605093
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aspects of the cellular pharmacology of N-l-leucyldoxorubicin in human tumor cell lines.
    Bennis S; Garcia C; Robert J
    Biochem Pharmacol; 1993 May; 45(9):1929-31. PubMed ID: 8494552
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.